Malaria vaccines


malaria vaccine is a vaccine that is used to prevent malaria. The only approved vaccine as of 2015 is RTS,S, known by the trade name Mosquirix. It requires four injections, and has a relatively low efficacy. Due to this low efficacy, the World Health Organization (WHO) does not recommend the routine use of the RTS,S vaccine in babies between 6 and 12 weeks of age.A WHO-led implementation program is piloting the vaccine in three high-malaria countries in Africa in 2019. The first phase of the project, covered by grants from Unit aid, Gavi and the Global Fund, is planned to establish the feasibility, impact and safety of RTS, S, when used as part of a routine immunization program. Research continues into recombinant protein, attenuated whole organism and viral vectored vaccines.

Coronavirus Conference | Covid-19 Pandemic | Latest invention and Researches on Covid-19 | World Infectious Diseases 2021

 


    Related Conference of Malaria vaccines

    January 24-25, 2022

    2nd European Congress on Hematology

    Prague, Czech Republic
    January 24-25, 2022

    2nd World Congress on Hematology and Genetic Blood Disorders

    Prague, Czech Republic
    March 14-15, 2022

    20th World Hematology Congress

    London, UK

    Malaria vaccines Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in